Loading...
Market
How will the market react to Wegovy's trial results by end of 2024?
2
Resolution / Starting Odds
Significant increase (>10%) • 25%
Moderate increase (5-10%) • 25%
No significant change • 25%
Decrease • 25%
Stock price data from financial markets
Story
Novo Nordisk's Wegovy Shows Significant Improvement in MASH Trial for Liver Disease
Nov 1, 2024, 01:22 PM
Novo Nordisk's semaglutide 2.4 mg, marketed as Wegovy, has demonstrated significant improvements in liver fibrosis and MASH (metabolic-associated steatohepatitis) resolution in the ESSENCE trial. The trial, which involved 1,200 adults, showed that after 72 weeks, 37% of patients treated with semaglutide experienced improvement in liver fibrosis compared to 22.5% on placebo. Additionally, 62.9% of treated patients achieved MASH resolution versus 34.1% on placebo. Wegovy, primarily a weight-loss drug, also showed potential in treating obesity-associated liver disease. The company plans to file for regulatory approvals in the US and EU in the first half of 2025. Detailed results from the ESSENCE trial will be presented at an upcoming scientific conference.
View original story
Similar markets
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
0 • 25%
1-3 • 25%
4-6 • 25%
More than 6 • 25%
Yes • 50%
No • 50%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Under 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Over 30% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Approved for MASH treatment • 25%
Approved with conditions • 25%
Not approved • 25%
Decision delayed • 25%
Exceeds expectations • 25%
Meets expectations • 25%
Falls short of expectations • 25%
Trial cancelled • 25%
Less than 20% • 25%
20% to 30% • 25%
31% to 40% • 25%
More than 40% • 25%
Ban the drugs • 25%
Issue safety warnings • 25%
No action taken • 25%
Other actions • 25%